Oxybutynin for Androgen Deprivation–Associated Hot Flashes in Prostate Cancer


Get Permission

Thomas J. Smith, MD

Thomas J. Smith, MD

In a letter to the editor of The New England Journal of Medicine, Thomas J. Smith, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, and colleagues described the successful use of oxybutynin to treat hot flashes in a patient receiving androgen-deprivation therapy (ADT) for prostate cancer. As noted by the authors, nonhormonal treatments of menopausal hot flashes in women generally have been found to have little efficacy in men receiving ADT for prostate cancer. Oxybutynin has been shown to be effective for refractory hot flashes in women, with one study showing improvement with the agent in 73% of women vs 26% with placebo.

In the case reported, a 65-year-old patient had a prostate-specific antigen–only recurrence detected after radical prostatectomy. He was receiving gabapentin at 300 mg 3 times a day for neuropathic pain and continued on this treatment while starting neoadjuvant and concurrent treatment with depot leuprolide at 22.5 mg every 3 months and bicalutamide at 50 mg daily for 6 months, with radiotherapy scheduled to begin after 3 months.

After 2 weeks, the patient experienced an abrupt onset of drenching hot flashes that occurred every 20 to 30 minutes beginning at 2:30 AM every night, preventing the patient from sleeping. No relief was achieved with the addition of extended-release venlafaxine at 75 mg or an increase in gabapentin dose to 900 mg at night (1,500 mg/d total) for more than 3 weeks.

Oxybutynin Treatment

The patient then started on oxybutynin at 5 mg twice a day, which provided relief from the sweating within 2 hours of dosing and permitted the patient to sleep through the night. He continued to take oxybutynin at 1.25 to 2.5 mg twice a day for 40 days, experiencing only transient hourly body warmth. Gabapentin and venlafaxine were tapered and stopped without recurrence of the hot flashes and sweating. The hot flashes resumed when the patient subsequently stopped oxybutynin due to insomnia, dry mouth, and restless leg syndrome. Restarting of oxybutynin at 2.5 mg twice a day produced relief from hot flashes within hours. Insomnia was treated with intermittent zolpidem.

The authors concluded, “We hope that this case report of successful treatment of refractory hot flashes in a man undergoing androgen deprivation for treatment of prostate cancer will stimulate interest in the oxybutynin class of drugs for hot flashes in men.” ■

Smith TJ, et al: N Engl J Med 378:1745-1746, 2018.


Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.